Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ondansetron + metoclopramide is a combination of two antiemetic medications used to prevent and treat nausea and vomiting. Ondansetron is a selective 5-HT3 receptor antagonist, while metoclopramide is a dopamine antagonist and prokinetic agent. This combination has been studied for post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Studies suggest that the combination may be more effective than either agent alone in certain clinical scenarios, particularly after sleeve gastrectomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ondansetron + metoclopramide.